Introduction

This page provides a comprehensive analysis of the known insider trading history of Brett R Hagen. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Brett R Hagen has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
Chief Accounting Officer 1,925
See Remarks 21,100
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Brett R Hagen. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Brett R Hagen as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-27 2025-03-26 4 KLRS Kalaris Therapeutics, Inc.
Common Stock
S - Sale -907 1,925 -32.03 8.97 -8,135 17,266
2025-02-24 2025-02-21 4 ALVR Allovir, Inc.
Common Stock
S - Sale -96 2,832 -3.28 10.08 -967 28,535
2025-01-27 2025-01-23 4 ALVR Allovir, Inc.
Common Stock
S - Sale -4 2,928 -0.14 9.94 -40 29,105
2025-01-27 2025-01-23 4 ALVR Allovir, Inc.
Common Stock
S - Sale -32 2,932 -1.08 9.45 -303 27,719
2025-01-13 2025-01-10 4 ALVR Allovir, Inc.
Common Stock
S - Sale -332 68,174 -0.48 0.44 -146 30,003
2024-11-20 2024-11-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale -554 68,506 -0.80 0.55 -304 37,576
2024-11-06 2024-11-05 4 ALVR Allovir, Inc.
Common Stock
S - Sale -1,655 69,060 -2.34 0.86 -1,431 59,730
2024-10-23 2024-10-22 4 ALVR Allovir, Inc.
Common Stock
S - Sale -486 70,715 -0.68 0.77 -373 54,295
2024-10-23 2024-10-21 4 ALVR Allovir, Inc.
Common Stock
S - Sale -479 71,201 -0.67 0.78 -373 55,466
2024-10-04 2024-10-03 4 ALVR Allovir, Inc.
Common Stock
S - Sale -301 71,680 -0.42 0.81 -245 58,405
2024-08-20 2024-08-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale -544 71,981 -0.75 0.76 -413 54,670
2024-08-07 2024-08-05 4 ALVR Allovir, Inc.
Common Stock
S - Sale -1,692 72,525 -2.28 0.73 -1,243 53,291
2024-07-23 2024-07-22 4 ALVR Allovir, Inc.
Common Stock
S - Sale -481 74,217 -0.64 0.74 -356 54,861
2024-07-23 2024-07-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale -479 74,698 -0.64 0.75 -359 56,031
2024-07-03 2024-07-02 4 ALVR Allovir, Inc.
Common Stock
S - Sale -304 75,177 -0.40 0.72 -219 54,127
2024-05-21 2024-05-17 4 ALVR Allovir, Inc.
Common Stock
S - Sale -541 75,481 -0.71 0.75 -405 56,558
2024-05-07 2024-05-03 4 ALVR Allovir, Inc.
Common Stock
S - Sale -1,597 76,022 -2.06 0.80 -1,271 60,514
2024-04-23 2024-04-22 4 ALVR Allovir, Inc.
Common Stock
S - Sale -480 77,619 -0.61 0.75 -360 58,214
2024-04-23 2024-04-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale -473 78,099 -0.60 0.75 -355 58,621
2024-04-04 2024-04-02 4 ALVR Allovir, Inc.
Common Stock
S - Sale -281 78,572 -0.36 0.77 -217 60,658
2024-02-22 2024-02-20 4 ALVR Allovir, Inc.
Common Stock
S - Sale -494 78,853 -0.62 0.70 -343 54,819
2024-02-09 2024-02-08 4 ALVR Allovir, Inc.
Common Stock
S - Sale -11,150 79,347 -12.32 0.67 -7,494 53,329
2024-02-06 2024-02-05 4 ALVR Allovir, Inc.
Common Stock
S - Sale -5,792 90,497 -6.02 0.67 -3,881 60,633
2024-01-25 2024-01-23 4 ALVR Allovir, Inc.
Common Stock
S - Sale -901 96,289 -0.93 0.67 -604 64,591
2024-01-08 2024-01-04 4 ALVR Allovir, Inc.
Common Stock
S - Sale -310 97,190 -0.32 0.64 -198 62,104
2024-01-02 2023-12-27 4 ALVR Allovir, Inc.
Common Stock
S - Sale -28,335 97,500 -22.52 0.74 -20,838 71,702
2023-11-21 2023-11-17 4 ALVR Allovir, Inc.
Common Stock
S - Sale -403 125,835 -0.32 1.63 -657 205,249
2023-10-23 2023-10-20 4 ALVR Allovir, Inc.
Common Stock
S - Sale -357 126,238 -0.28 1.54 -550 194,533
2023-10-23 2023-10-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale -358 126,595 -0.28 1.58 -566 200,020
2023-10-05 2023-10-03 4 ALVR Allovir, Inc.
Common Stock
S - Sale -222 126,953 -0.17 1.98 -439 250,897
2023-08-21 2023-08-17 4 ALVR Allovir, Inc.
Common Stock
S - Sale -1,653 127,175 -1.28 2.50 -4,125 317,365
2023-07-21 2023-07-20 4 ALVR Allovir, Inc.
Common Stock
S - Sale -342 128,828 -0.26 3.35 -1,145 431,239
2023-07-21 2023-07-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale -342 129,170 -0.26 3.56 -1,218 460,039
2023-06-13 2023-06-09 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -5,045 129,512 -3.75 5.64 -28,453 730,422
2023-04-21 2023-04-20 4 ALVR Allovir, Inc.
Common Stock
S - Sale -349 134,557 -0.26 3.63 -1,265 487,836
2023-04-21 2023-04-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale -348 134,906 -0.26 3.71 -1,291 500,326
2023-02-03 2023-02-02 4 ALVR Allovir, Inc.
Common Stock
A - Award 61,250 135,254 82.77
2023-01-23 2023-01-20 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -338 74,004 -0.45 5.14 -1,739 380,662
2023-01-23 2023-01-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -1,557 74,342 -2.05 5.08 -7,906 377,486
2022-11-14 2022-11-11 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -18,011 75,899 -19.18 8.18 -147,258 620,550
2022-11-14 2022-11-10 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -5,989 93,910 -6.00 8.00 -47,925 751,477
2022-10-26 2022-10-20 4/A ALVR Allovir, Inc.
Common Stock
S - Sale -345 113,233 -0.30 9.36 -3,229 1,059,940
2022-10-24 2022-10-24 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -2,000 99,899 -1.96 8.13 -16,269 812,628
2022-10-24 2022-10-21 4 ALVR Allovir, Inc.
Common Stock
S - Sale -11,334 101,899 -10.01 8.45 -95,800 861,291
2022-10-24 2022-10-19 4 ALVR Allovir, Inc.
Common Stock
S - Sale -345 113,233 -0.30 9.36 -3,229 1,059,940
2022-08-17 2022-08-16 4 ALVR Allovir, Inc.
Common Stock
A - Award 20,000 113,578 21.37
2022-07-06 2022-07-01 4 ALVR Allovir, Inc.
Common Stock
A - Award 10,500 93,578 12.64
2022-04-22 2022-04-20 4 ALVR Allovir, Inc.
Common Stock
S - Sale -276 80,368 -0.34 6.68 -1,845 537,204
2022-04-04 2022-01-18 4 ALVR Allovir, Inc.
Stock Option (Right to Buy)
A - Award 42,558 42,558
2022-04-04 2022-01-18 4 ALVR Allovir, Inc.
Common Stock
A - Award 17,442 80,644 27.60
2022-01-24 2022-01-20 4 ALVR Allovir, Inc.
Common Stock
S - Sale -1,563 63,202 -2.41 8.75 -13,680 553,182
2021-02-23 2021-02-22 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -800 64,765 -1.22 43.14 -34,509 2,793,722
2021-02-19 2021-02-18 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -541 65,565 -0.82 40.39 -21,853 2,648,374
2021-02-19 2021-02-18 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -200 66,106 -0.30 39.36 -7,871 2,601,602
2021-02-18 2021-02-17 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -200 66,306 -0.30 41.68 -8,336 2,763,634
2021-02-18 2021-02-17 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -1,300 66,506 -1.92 41.17 -53,520 2,737,999
2021-02-18 2021-02-17 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -220 67,806 -0.32 39.86 -8,769 2,702,835
2021-02-18 2021-02-17 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -600 68,026 -0.87 38.56 -23,138 2,623,307
2021-02-18 2021-02-16 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -300 68,626 -0.44 42.67 -12,802 2,928,498
2021-02-18 2021-02-16 4 ALVR Allovir, Inc.
Common Stock
S - Sale X -2,750 68,926 -3.84 41.82 -115,014 2,882,713
2021-01-21 2021-01-19 4 ALVR Allovir, Inc.
Stock Option (Right to Buy)
A - Award 32,500 32,500
2021-01-21 2021-01-19 4 ALVR Allovir, Inc.
Common Stock
A - Award 17,500 71,676 32.30
2020-08-05 2020-08-03 4 ALVR Allovir, Inc.
Series B Convertible Preferred Stock
C - Conversion -6,500 0 -100.00
2020-08-05 2020-08-03 4 ALVR Allovir, Inc.
Common Stock
C - Conversion 4,361 54,176 8.75
2020-07-31 2020-07-29 4 ALVR Allovir, Inc.
Stock Option (Right to Buy)
A - Award 43,400 43,400
2020-07-30 3 ALVR Allovir, Inc.
Common Stock
99,630
2020-07-30 3 ALVR Allovir, Inc.
Common Stock
99,630
2020-07-30 3 ALVR Allovir, Inc.
Common Stock
99,630
2017-04-05 2017-04-03 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Employee Stock Option (Right to Buy)
A - Award 21,100 21,100
2016-08-08 2016-08-04 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Employee stock Option (Right to Buy)
A - Award 7,500 7,500
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)